NEW YORK (GenomeWeb) – GATC Biotech today announced it has signed a worldwide commercial agreement with Molecular Health.

Under the terms of the agreement, GATC Biotech will market and support Molecular Health's TreatmentMap tumor profiling system, which includes a next-generation sequencing-based test which looks at 500 cancer-linked genes to guide treatment strategies. Molecular Health has launched TreatmentMap in the US and in Germany and GATC Biotech will work with the company to increase adoption of the technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.